Quantcast
Home > Quotes > SURF

Surface Oncology, Inc. Common Stock (SURF) Quote & Summary Data

SURF 
$4.17
*  
0.05
1.18%
Get SURF Alerts
*Delayed - data as of Mar. 22, 2019  -  Find a broker to begin trading SURF now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 4.66 / $ 4.16
Share Volume
46,625
50 Day Avg. Daily Volume
60,999
Previous Close
$ 4.22
52 Week High / Low
$ 18.18 / $ 3.4492
Market Cap
116,049,307
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
46,625
50 Day Avg. Daily Volume:
60,999

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.47

Trading Range

The current last sale of $4.17 is 20.90% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 4.66 $ 18.18
 Low: $ 4.16 $ 3.4492

Company Description (as filed with the SEC)

We are a clinical-stage immuno-oncology company focused on using our specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment, or the TME, for the development of next-generation cancer therapies. While first-generation immuno-oncology therapies, such as checkpoint inhibitors, are a remarkable therapeutic advancement, we believe most patients do not achieve durable clinical benefit primarily because these therapies focus on only one element of the complex and interconnected immunosuppressive TME. We believe there is a significant opportunity to more broadly engage both the innate and adaptive arms of the immune system in a multi-faceted, coordinated and patient-specific approach, to meaningfully improve cure rates for patients with a variety of cancers.  ... More ...  



Risk Grade

Where does SURF fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 4.25
Open Date:
Mar. 22, 2019
Close Price:
$ 4.17
Close Date:
Mar. 22, 2019


Consensus Recommendation

Analyst Info